Oral Glucosamine in the Treatment of Temporomandibular Joint Osteoarthritis: A Systematic Review.

Abstract

Temporomandibular disorders (TMDs) occur frequently within the general population and are the most common non-dental cause of orofacial pain. Temporomandibular joint osteoarthritis (TMJ OA) is a degenerative joint disease (DJD). There have been several different methods of treatment of TMJ OA listed, including pharmacotherapy among others. Due to its anti-aging, antioxidative, bacteriostatic, anti-inflammatory, immuno-stimulating, pro-anabolic and anti-catabolic properties, oral glucosamine seems to be a potentially very effective agent in the treatment of TMJ OA. The aim of this review was to critically assess the efficacy of oral glucosamine in the treatment of TMJ OA on the basis of the literature. PubMed and Scopus databases were analyzed with the keywords: (temporomandibular joints) AND ((disorders) OR (osteoarthritis)) AND (treatment) AND (glucosamine). After the screening of 50 results, eight studies have been included in this review. Oral glucosamine is one of the symptomatic slow-acting drugs for osteoarthritis. There is not enough scientific evidence to unambiguously confirm the clinical effectiveness of glucosamine supplements in the treatment of TMJ OA on the basis of the literature. The most important aspect affecting the clinical efficacy of oral glucosamine in the treatment of TMJ OA was the total administration time. Administration of oral glucosamine for a longer period of time, i.e., 3 months, led to a significant reduction in TMJ pain and a significant increase in maximum mouth opening. It also resulted in long-term anti-inflammatory effects within the TMJs. Further long-term, randomized, double-blind studies, with a unified methodology, ought to be performed to draw the general recommendations for the use of oral glucosamine in the treatment of TMJ OA.

• Authors: Marcin Derwich, Bartłomiej Górski, Elie Amm, Elżbieta Pawłowska
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 5 (Mar 03 2023) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 36902359 (Publication Type: Systematic Review, Journal Article, Review)

Chemical References

• Glucosamine
• Anti-Inflammatory Agents

Topics

• Humans
• Glucosamine
• Osteoarthritis (drug therapy)
• Temporomandibular Joint
• Anti-Inflammatory Agents (therapeutic use)
• Facial Pain (drug therapy)
• Randomized Controlled Trials as Topic